Aprea Therapeutics' Q3 net loss narrows

Aprea Therapeutics

12/11/2025 13:38

Overview

Aprea Q3 net loss narrows to $3.0 mln from $3.8 mln in prior yr

Company's cash position expected to support operations into Q4 2026

Clinical progress in WEE1 and ATR inhibitor programs noted

Outlook

Aprea plans to explore combination strategies for ATRN-119 with radiation or checkpoint inhibitors

Company progressing with dose escalation for APR-1051 to 150 mg once daily

Aprea has cash runway into the fourth quarter of 2026

Result Drivers

Research and Development (R&D) expenses were $1.6 million for the quarter ended September 30, 2025, compared to $2.8 million for the third quarter of 2024

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 EPS
-$0.47
Q3 Net Income
-$3 mln
Q3 Operating Income
-$3.10 mln


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Wall Street's median 12-month price target for Aprea Therapeutics Inc is $10.50, about 87.4% above its November 11 closing price of $1.32

Press Release: ID:nGNX6vfgXH

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)